Novartis abandons experimental heart drug after stunning trial failure

Novartis is abandoning an experimental heart drug that analysts once considered a potential blockbuster after a stunning study failure, according to Reuters. The setback adds to trial failures in the drugmakers' cardiovascular programs, including Novo Nordisk's halted heart drug studies.

Detected & updated continuously · Source: Nebula